PH12020500295A1 - Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same - Google Patents
Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the sameInfo
- Publication number
- PH12020500295A1 PH12020500295A1 PH12020500295A PH12020500295A PH12020500295A1 PH 12020500295 A1 PH12020500295 A1 PH 12020500295A1 PH 12020500295 A PH12020500295 A PH 12020500295A PH 12020500295 A PH12020500295 A PH 12020500295A PH 12020500295 A1 PH12020500295 A1 PH 12020500295A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical composition
- losartan
- rosuvastatin
- diabetes
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170134809 | 2017-10-17 | ||
KR1020180112376A KR20190043076A (ko) | 2017-10-17 | 2018-09-19 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제 |
PCT/KR2018/012213 WO2019078592A1 (fr) | 2017-10-17 | 2018-10-17 | Composition pharmaceutique pour la prévention ou le traitement de maladies cardiovasculaires accompagnées de diabète, comprenant de l'amlodipine, du losartan et de la rosuvastatine, et préparation composite comprenant celle-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12020500295A1 true PH12020500295A1 (en) | 2020-11-09 |
Family
ID=66174145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12020500295A PH12020500295A1 (en) | 2017-10-17 | 2020-02-10 | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same |
Country Status (12)
Country | Link |
---|---|
KR (1) | KR20190043076A (fr) |
CN (1) | CN111511369A (fr) |
CO (1) | CO2020001514A2 (fr) |
CR (1) | CR20200096A (fr) |
EA (1) | EA202090165A1 (fr) |
EC (1) | ECSP20014155A (fr) |
MX (1) | MX2020001681A (fr) |
NI (1) | NI202000017A (fr) |
PH (1) | PH12020500295A1 (fr) |
SG (1) | SG11202000622WA (fr) |
TW (1) | TW201922243A (fr) |
WO (1) | WO2019078592A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022015607A (es) * | 2020-06-09 | 2023-01-24 | Hanmi Pharm Ind Co Ltd | Preparacion farmaceutica de complejo, para prevenir o tratar enfermedades cardiovasculares, que compone de amlodipina, losartan y clortalidona en comprimido monocapa. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100742432B1 (ko) | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법 |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
PT2136798E (pt) * | 2007-03-21 | 2015-10-15 | Sigma Tau Ind Farmaceuti | Composição útil para a prevenção da diabetes tipo 2 e sua complicações em pacientes pré-diabéticos com resistência à insulina |
WO2009127974A2 (fr) * | 2008-02-22 | 2009-10-22 | 한올제약주식회사 | Préparation pharmaceutique pour le traitement de maladies cardiovasculaires |
KR101910901B1 (ko) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
CN108156807A (zh) * | 2015-06-30 | 2018-06-12 | 韩美药品株式会社 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
-
2018
- 2018-09-19 KR KR1020180112376A patent/KR20190043076A/ko active Search and Examination
- 2018-10-16 TW TW107136415A patent/TW201922243A/zh unknown
- 2018-10-17 SG SG11202000622WA patent/SG11202000622WA/en unknown
- 2018-10-17 MX MX2020001681A patent/MX2020001681A/es unknown
- 2018-10-17 WO PCT/KR2018/012213 patent/WO2019078592A1/fr active Application Filing
- 2018-10-17 CR CR20200096A patent/CR20200096A/es unknown
- 2018-10-17 EA EA202090165A patent/EA202090165A1/ru unknown
- 2018-10-17 CN CN201880081280.XA patent/CN111511369A/zh not_active Withdrawn
-
2020
- 2020-02-10 PH PH12020500295A patent/PH12020500295A1/en unknown
- 2020-02-11 CO CONC2020/0001514A patent/CO2020001514A2/es unknown
- 2020-02-26 EC ECSENADI202014155A patent/ECSP20014155A/es unknown
- 2020-02-28 NI NI202000017A patent/NI202000017A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA202090165A1 (ru) | 2020-07-10 |
KR20190043076A (ko) | 2019-04-25 |
CO2020001514A2 (es) | 2020-02-28 |
CN111511369A (zh) | 2020-08-07 |
ECSP20014155A (es) | 2020-04-22 |
SG11202000622WA (en) | 2020-02-27 |
CR20200096A (es) | 2020-04-03 |
MX2020001681A (es) | 2020-07-13 |
TW201922243A (zh) | 2019-06-16 |
WO2019078592A1 (fr) | 2019-04-25 |
NI202000017A (es) | 2020-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
WO2015165413A8 (fr) | Nouveau conjugué anticorps-médicament stable, procédé pour le préparer, et son utilisation | |
WO2017083304A8 (fr) | Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine | |
PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
EP3607963A4 (fr) | Médicament thérapeutique pour maladie fibreuse | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
EP3954395A4 (fr) | Composition pharmaceutique pour traitement des maladies musculaires | |
SA520411635B1 (ar) | A2a مشتق حلقي مدمج كمثبط مستقبل | |
EP3231436A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace | |
WO2015173701A3 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
WO2019194773A3 (fr) | Combinaison contenant de la linagliptine et de la metformine | |
WO2016006974A3 (fr) | Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation | |
WO2016006975A3 (fr) | Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
WO2015001541A3 (fr) | Composition de film pharmaceutique | |
MD4763C1 (ro) | Compoziţie farmaceutică | |
WO2016122288A3 (fr) | Formulation combinée comprenant un dérivé de verbénone et un agent thérapeutique pour une reperfusion pour la prévention ou le traitement de maladies cérébrovasculaires, de l'artériosclérose ou de maladies cardio-vasculaires | |
EP4038064C0 (fr) | Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
JOP20200005A1 (ar) | تركيبات صيدلية | |
WO2019059868A3 (fr) | Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz | |
EP3530269A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement du diabète et/ou de l'hyperlipidémie comprenant de la midorine ou un sel pharmaceutiquement acceptable de celle-ci en tant que principe actif | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
SG10201903656RA (en) | Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor | |
EP2924024A3 (fr) | Formes solides de composés d'hydrochlorure de lorcaserin |